Alerta

COMBINATION THERAPY FOR CLASSIC HODGKIN'S LYMPHOMA

Resumen de: WO2025223394A1

The present application relates to a pharmaceutical composition comprising i) a recombinant fusion protein and ii) an anti-PD-1 antibody, wherein the recombinant fusion protein comprises a mutated SIRPα D1 domain linked to a functional IgG1 heavy chain constant region, wherein the mutated SIRPα D1 domain comprises the amino acid sequence of SEQ ID NO: 2. The present application also relates to use of the pharmaceutical composition in preparation of a medicament for treating classic Hodgkin's lymphoma (cHL), e.g., relapsed or refractory cHL.

PURINE COVALENT BASED CDK12 INHIBITORS

Resumen de: WO2025226831A1

Disclosed are purine derivatives of formulae (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods involving the inventive compounds or compositions for treating and/or preventing cell proliferative diseases including certain cancers of breast, brain, ovarian, lung, colorectal cancer, leukemias, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma and inflammatory and myotonic dystrophy type 1 diseases in a mammal. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of kinases, such as a cyclin-dependent kinases (CDK) (e.g., CDK12/13), and therefore, induce potent antiproliferative and apoptotic effects and/or inhibit transcription in the subject.

CDK12 INHIBITORS WITH IMIDAZOLE1,2-A PYRAZINES

Resumen de: WO2025226846A1

Disclosed are substituted purine derivatives of formulae (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods involving the inventive compounds or compositions for treating and/or preventing cell proliferative diseases including certain cancers of breast, brain, ovarian, lung, colorectal cancer, leukemias, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma and inflammatory and myotonic dystrophy type 1 diseases in a mammal. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of kinases, such as a cyclin-dependent kinases (CDK) (e.g., CDK12/13), and degrade some other proteins (including cycK) and therefore, induce potent antiproliferative and apoptotic effects and/or inhibit transcription in the subject.

METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE

Resumen de: WO2025227007A1

Disclosed herein are 4,6-substituted-2-(3'-1,1'-biphenyl-4-yl)quinoline analogs and pharmaceutically acceptable salts thereof that are inhibitors of dihydroorotate dehydrogenase (DHODH) with properties, including stability and bioavailability as disclosed herein. Also disclosed herein are methods of making the analogs and salts thereof. The disclosed analogs and salts thereof can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation.

METHODS FOR TREATING LOWER RISK MYELODYSPLASTIC SYNDROME

Resumen de: WO2024137713A1

The present disclosure relates to the use of pelabresib, and pharmaceutically acceptable salts and hydrates thereof, for treating lower risk myelodysplastic syndrome (LR-MDS) and conditions associated therewith.

HETERO (AROMATIC) RING-SUBSTITUTED CYCLIC DIAMINE COMPOUND AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING AND/OR PREVENTING TUMORS

Resumen de: WO2025218293A1

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and/or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

REAGENTS AND METHODS FOR DETECTING OR MODULATING CBL AND/OR CBL-B IN PATIENTS

Resumen de: WO2025217743A1

Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. The diagnosis of SLE is challenging because signs and symptoms vary considerably from person to person, may change over time, and may overlap with those of many other disorders. There is thus a need for better tools and assays for the diagnosis and assessment of SLE. The present application discloses novel methods for the diagnosis and follow-up of SLE based on the detection of the levels of Casitas B-lineage lymphoma (CBL) and/or CBL-B in T lymphocytes from a subject, as well as novel methods for treating a subject suffering from SLE or preventing the development of SLE in an at-risk subject through the administration of an agent that increases the expression or activity of CBL and/or CBL-B in T lymphocytes from the subject, and/or the depletion of ICOS+ T cells.

HUMANIZED ANTI-CD45 ANTIBODIES AND USES THEREOF

Resumen de: US2025326856A1

Novel chimeric and/or humanized forms of the anti-CD45 BC8 antibody are described. The disclosed chimeric or humanized antibodies can be used as research, diagnostic, or therapeutic tools against CD45-related disorders, such as hematologic malignancies including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), other myeloid and lymphoid disorders, other cancers, as well as non-malignant disorders, such as autoimmune disorders, infections, inherited blood disorders, and metabolic disorders.

METHODS OF USE AND COMPOSITIONS OF BISBENZYLISOQUINOLINES FOR THE TREATMENT OF MALIGNANCIES

Resumen de: AU2024238830A1

The present disclosed invention provides pharmaceutical compositions and methods of use for bisbenzylisoquinolines such as 6,6',7,12-tetramethoxy-2,2'-dimethyl-berbaman, and analogs, derivatives, isomers, and modified forms such as crystalline, salt forms, or a salt of this compound with a pharmaceutically acceptable acid or in combination with other agents to treat acute, chronic and pre-leukemic conditions as well as lymphomas and solid tumors. These include preneoplastic and neoplastic diseases and solid tumors including but not limited to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), atypical chronic myeloid leukemia (aCML), and acute myeloid leukemia (AML), polycythemia vera (PV), chronic lymphoblastic leukemia (CLL), myeloproliferative syndrome (MPS), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), myelofibrosis (MF), and polycythemia vera (PV).

ALK POLYPEPTIDES AND METHODS OF USE THEREOF

Resumen de: US2025325644A1

The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).

ZEBRAFISH MODEL OF HUMAN ACUTE MYELOID LEUKEMIA AND METHOD OF USE THEREOF

Resumen de: US2025324955A1

Genetically modified zebrafish, in which mutation combinations frequently identified in human AML are stably expressed in the stem cell population of the fish, are provided. The combination of mutations result in morphologic, cytochemical and molecular changes of its blood cells that are remarkably similar to those in human AML. The zebrafish model provides a foundation for the study of AML initiation and progression and a high throughput in vivo drug screening platform to identify personalized therapies for AML based on specific mutation combinations. The method of drug screening includes contacting embryos or adult fish containing mutations as disclosed herein, with a test agent, at test concentrations and test intervals to determine the therapeutic effect if any, of the test agent.

USE OF ANTI-HA-1 AND ANTI-HA-2 BINDING PROTEINS FOR TREATMENT OF AML, ALL, AND MDS

Resumen de: AU2025202444A1

TTC-018 USE OF ANTI-HA-1 AND ANTI-HA-2 BINDING PROTEINS FOR TREATMENT OF AML, ALL, AND MDS The present disclosure encompasses, among other things, methods and compositions for use in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic disorder (MDS) in subjects that received HCT. The present disclosure relates, at least in part, to T cells engineered to express particular T Cell Receptors (TCRs) and their use in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic disorder (MDS) in subjects that received HCT. TTC-018 USE OF ANTI-HA-1 AND ANTI-HA-2 BINDING PROTEINS FOR TREATMENT OF AML, ALL, AND MDS The present disclosure encompasses, among other things, methods and compositions for use in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic disorder (MDS) in subjects that received HCT. The present disclosure relates, at least in part, to T cells engineered to express particular T Cell Receptors (TCRs) and their use in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic disorder (MDS) in subjects that received HCT. pr - - - - - , , p r h e p r e s e n t d i s c l o s u r e e n c o m p a s s e s , a m o n g o t h e r t h i n g s , m e t h o d s a n d c o m p o s i t i o n s f o r u s e i n t h e t r e a t m e n t o f a c u t e m y e l o i d l e u k e m i a ( ) , a c u t e l y m p h o c y t i

ANTI-CLL1 SINGLE-DOMAIN ANTIBODY AND USE THEREOF

Nº publicación: EP4635981A1 22/10/2025

Solicitante:

CARBIOGENE THERAPEUTICS CO LTD [CN]
Carbiogene Therapeutics Co., Ltd

Resumen de: EP4635981A1

The present invention relates to an anti-CLL1 single-domain antibody and use thereof, specifically, to a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity and can specifically target CLL1-positive cells, and can be applied to the detection of CLL1 expression in bone marrow cells of acute myeloid leukemia (AML) patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating CLL1 target-related diseases (such as acute myeloid leukemia, myelodysplastic syndromes, or chronic myeloid leukemia), and can also be used in the preparation of CLL1-targeting chimeric antigen receptor (CAR) cells or diagnostic kits for CLL1 protein detection and the like. The single-domain antibody drug has a stable structure, small molecular size, ease of recombinant expression, and low production cost. It can be used alone or employed as a drug delivery system to carry related drugs, which has broad prospects and important significance in the fields of pharmaceutical application, clinical diagnosis, and related fields.